Evidence map›Paper›PMID 30546303›Full record

ArticleFrontiers in aging neuroscience2018

Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old.

Gorka Fernández-Eulate, Ainhoa Alberro, Maider Muñoz-Culla, Miren Zulaica, Mónica Zufiría, Myriam Barandiarán, Igone Etxeberria, José Javier Yanguas, Maria Mercedes Gallardo, Nora Soberón and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Gorka Fernández-EulateDepartment of Neurology, Donostia Universitary Hospital, San Sebastián, Spain.
Ainhoa AlberroNeurosciences Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Maider Muñoz-CullaNeurosciences Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Miren ZulaicaNeurosciences Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Mónica ZufiríaNeurosciences Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Myriam BarandiaránDepartment of Neurology, Donostia Universitary Hospital, San Sebastián, Spain.
Igone EtxeberriaDepartment of Personality, Assessment, and Psychological Treatments, Faculty of Psychology, University of the Basque UPV/EHU, San Sebastián, Spain.
José Javier YanguasMatia Fundazioa, San Sebastián, Spain.
Maria Mercedes GallardoTelomeres & Telomerase Group, Molecular Oncology Programme, Spanish National Cancer Research Center, Madrid, Spain.
Nora SoberónTelomeres & Telomerase Group, Molecular Oncology Programme, Spanish National Cancer Research Center, Madrid, Spain.
Ana María LacostaAraclon Biotech, Zaragoza, Spain.
Virginia Pérez-GrijalbaAraclon Biotech, Zaragoza, Spain.
Jesús CanudasAraclon Biotech, Zaragoza, Spain.
Noelia FandosAraclon Biotech, Zaragoza, Spain.
Pedro PesiniAraclon Biotech, Zaragoza, Spain.
Manuel SarasaAraclon Biotech, Zaragoza, Spain.
Begoña IndakoetxeaDepartment of Neurology, Donostia Universitary Hospital, San Sebastián, Spain.
Fermin MorenoDepartment of Neurology, Donostia Universitary Hospital, San Sebastián, Spain.
Itziar VergaraPrimary Health Area, Biodonostia Institute, San Sebastián, Spain.
David OtaeguiNeurosciences Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Maria BlascoTelomeres & Telomerase Group, Molecular Oncology Programme, Spanish National Cancer Research Center, Madrid, Spain.
Adolfo López de MunainDepartment of Neurology, Donostia Universitary Hospital, San Sebastián, Spain.
Biogipuzkoa Health Research Institute · ESSpanish National Cancer Research Centre · ESUniversity of the Basque Country · ESMatia Fundazioa · ESSpanish Clinical Research Network · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many factors may converge in healthy aging in the oldest old, but their association and predictive power on healthy or functionally impaired aging has yet to be demonstrated. By detecting healthy aging and in turn, poor aging, we could take action to prevent chronic diseases associated with age. We conducted a pilot study comparing results of a set of markers (peripheral blood mononuclear cell or PBMC telomere length, circulating Aβ peptides, anti-Aβ antibodies, and ApoE status) previously associated with poor aging or cognitive deterioration, and their combinations, in a cohort of "neurologically healthy" (both motor and cognitive) nonagenarians (

Indexed as

agingAmyloid-βcomposite neurologically healthy aging scoreelderstelomere

Identifiers

PMID30546303
PMCPMC6280560
OpenAlexW2902057584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.